CIOMS and WHO in Pharmacovigilance: Roles, Working Groups and the Global Drug Safety Framework

In our previous post, we discussed the role of the International Council for Harmonization (ICH) in establishing harmonized regulatory guidelines for pharmacovigilance. However, global drug safety does not rely solely on ICH.

Two key international organizations also play a major role in shaping pharmacovigilance concepts and practices: the Council for International Organizations of Medical Sciences (CIOMS) and the World Health Organization (WHO).

While ICH focuses mainly on regulatory harmonization, CIOMS and WHO contribute to the scientific, ethical, and public health foundations of pharmacovigilance. Their guidance supports consistent drug safety monitoring across countries, healthcare systems, and patient populations.

Understanding the roles of CIOMS and WHO is essential for professionals in pharmacovigilance for several reasons:

- Their recommendations influence global safety practices.

- Their principles support signal detection and causality assessment.

This post will explain what CIOMS and WHO are, how they contribute to pharmacovigilance, and why their roles are important for both newcomers and experienced professionals in the field.

Their work complements the ICH pharmacovigilance guidelines

Regulatory authorities worldwide rely on their frameworks for decision-making.

While ICH provides harmonized regulatory requirements, organizations like CIOMS and WHO strengthen the scientific, ethical, and public health foundations that support effective pharmacovigilance worldwide.

What is CIOMS?

The Council for International Organizations of Medical Sciences (CIOMS) is an international, non-governmental, non-profit organization established in 1949 jointly by the World Health Organization (WHO) and UNESCO.

CIOMS represents a broad section of the global biomedical scientific community, including:

National academies of sciences
Medical research councils
Professional biomedical organizations

The mission of CIOMS is to advance public health by developing scientific and ethical guidance related to:

Health research
Medical product development
Pharmacovigilance and medicine safety

CIOMS works in official relations with WHO and acts as a scientific advisory body that supports global health decision-making.

Role of CIOMS in Pharmacovigilance

CIOMS plays a foundational role in pharmacovigilance by providing conceptual, scientific, and ethical guidance that supports safe use of medicines throughout their lifecycle.

Unlike regulatory bodies, CIOMS does not issue legally binding rules. Instead, it develops internationally accepted recommendations that are widely followed by:

Regulatory authorities
Pharmaceutical companies
Clinical researchers
Pharmacovigilance professionals

These recommendations influence how adverse events are assessed, how safety data is interpreted, and how benefit–risk decisions are made globally.

Key Contributions of CIOMS to Pharmacovigilance

1. CIOMS and Adverse Event Reporting

CIOMS contributed to the early development of standardized adverse event reporting formats, which helped harmonize safety data collection during:

Clinical trials
Post-marketing surveillance

These concepts later influenced global pharmacovigilance standards, including ICH safety guidelines.

2. CIOMS and Causality Assessment

CIOMS provided the scientific principles used to assess the relationship between a suspected drug and an adverse event.

CIOMS guidance emphasizes evaluating:

Temporal relationship between drug exposure and event onset
Dechallenge and rechallenge information
Presence of alternative causes (disease, alcohol, concomitant drugs)
Existing knowledge of the drug’s safety profile

While CIOMS did not publish a formal causality “scale,” its concepts strongly influenced the WHO-UMC causality assessment system, which is now widely used in routine pharmacovigilance practice.

📌 Key point: CIOMS provides the conceptual framework, while WHO-UMC provides the practical classification system.

CIOMS Working Groups (Scientific Guidance)

CIOMS develops its guidance through expert working groups, each addressing key pharmacovigilance challenges.

Important CIOMS working groups include:

Important CIOMS working groups include:

CIOMS I – International reporting of adverse drug reactions
CIOMS II – International reporting of periodic safety information
CIOMS III – Core clinical safety information
CIOMS V – Current challenges in pharmacovigilance
CIOMS VI – Risk management and safety planning
CIOMS VIII – Signal detection
CIOMS XI – Evidence synthesis and benefit–risk assessment

These reports laid the groundwork for:

PSUR and PBRER concepts
Signal management systems
Risk management planning

4. CIOMS and Signal Detection

CIOMS guidance supports systematic approaches to signal detection, including:

Evaluation of spontaneous adverse event reports
Review of clinical trial and post-marketing data
Assessment of consistency, strength, and plausibility of safety signals

CIOMS emphasizes scientific judgment and evidence integration, rather than relying on a single data source.

5. CIOMS and Benefit–Risk Assessment

CIOMS introduced structured thinking around benefit–risk evaluation, helping determine whether a medicine’s benefits continue to outweigh its risks.

This concept later influenced:

ICH E2C(R2) – Periodic Benefit–Risk Evaluation Reports (PBRERs)
Regulatory decision-making on labeling updates, restrictions, or risk minimization measures

CIOMS and Research Ethics

In addition to pharmacovigilance, CIOMS is globally respected for its ethical guidelines in biomedical research.

CIOMS ethical guidance focuses on:

Protection of human research participants
Ethical conduct of clinical trials
Safeguarding vulnerable populations
Responsible data collection and reporting

These ethics guidelines are widely applied, especially in multinational and low-resource research settings.

Role of WHO in Pharmacovigilance

Introduction: Why WHO Matters in Pharmacovigilance

After understanding the scientific and ethical foundations of pharmacovigilance through CIOMS, the next key pillar in global drug safety is the World Health Organization (WHO).

While CIOMS provides conceptual guidance and ICH provides regulatory harmonization, WHO focuses on public health–oriented pharmacovigilance systems. WHO plays a central role in ensuring that medicine safety monitoring is implemented consistently across countries, especially in low- and middle-income regions.

WHO supports national authorities in detecting, assessing, and preventing adverse effects of medicines to protect patients worldwide.

What Is WHO?

The World Health Organization (WHO) is a specialized agency of the United Nations, established in 1948, responsible for international public health.

In pharmacovigilance, WHO:

Provides global leadership on medicine safety
Supports countries in building PV systems
Coordinates international collaboration on adverse drug reaction monitoring

According to the WHO, pharmacovigilance is defined as:

The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem.

This definition forms the foundation of all pharmacovigilance activities worldwide.

WHO Programme for International Drug Monitoring (PIDM)

One of WHO’s most important contributions to pharmacovigilance is the Programme for International Drug Monitoring (PIDM).

Purpose of PIDM

The PIDM was established to:

Promote international cooperation in medicine safety
Enable sharing of adverse drug reaction (ADR) data
Support early identification of global safety concerns

How PIDM Works

National pharmacovigilance centres from participating countries collect ADR reports
These reports are shared internationally to identify patterns not visible at a national level
This collaborative approach strengthens global signal detection

Uppsala Monitoring Centre (UMC)

The Uppsala Monitoring Centre (UMC) is a WHO Collaborating Centre for International Drug Monitoring, located in Sweden.

Role of UMC in Pharmacovigilance

UMC is responsible for:

Managing the global ADR database
Supporting signal detection activities
Developing pharmacovigilance tools and methodologies
Providing training and technical support to national PV centres

UMC acts as the operational arm of WHO’s international drug monitoring activities.

VigiBase: Global Database of ICSRs

VigiBase is the world’s largest global database of Individual Case Safety Reports (ICSRs).

Key Features of VigiBase

Contains ADR reports submitted by national PV centres
Covers medicines, vaccines, and biological products
Enables detection of rare and delayed adverse reactions
Supports global signal detection and trend analysis

Pooling safety data from many countries allows identification of risks that may not be detected within a single region.

WHO Guidance on Pharmacovigilance Systems

WHO provides practical guidance to help countries establish and strengthen pharmacovigilance systems, particularly where regulatory infrastructure is limited.

Areas Covered by WHO Guidance

Establishment of national PV centres
Development of ADR reporting mechanisms
Improving data quality and completeness
Encouraging reporting by healthcare professionals
Integration of pharmacovigilance into public health programs

WHO also publishes pharmacovigilance indicators to evaluate the performance of PV systems and identify areas for improvement.

WHO Role in Vaccine Safety and AEFI Monitoring

WHO plays a major role in vaccine pharmacovigilance, especially through monitoring Adverse Events Following Immunization (AEFI).

WHO Support in Vaccine Safety

Development of AEFI surveillance frameworks
Guidance on vaccine safety monitoring
Support during mass immunization programs
Safety monitoring during public health emergencies

This role became especially important during large-scale vaccination campaigns.

WHO Support for Low- and Middle-Income Countries

A key strength of WHO is its focus on equitable global health.

WHO supports low- and middle-income countries by:

Building pharmacovigilance capacity
Providing training and technical expertise
Supporting integration of PV into healthcare systems
Promoting harmonized safety practices globally

This ensures that medicine safety monitoring is not limited to high-income regions.

CIOMS vs ICH vs WHO: Quick Comparison

Aspect	CIOMS	WHO	ICH
Nature	Scientific advisory organization	Global public health authority	Regulatory harmonization body
Role in PV	Concepts, ethics, methodology	Global safety monitoring	Regulatory safety guidelines
Output	Scientific reports and recommendations	Programs, tools, and databases	Harmonized regulatory guidelines
Examples	Benefit–risk frameworks	WHO-UMC, VigiBase	ICH E2A–E2F

To learn more about international pharmacovigilance regulations, read our article on PV GUIDELINES

To understand the WHO-UMC causality assessment system, read our article on Causality Assessment in Pharmacovigilance.

Frequently Asked Questions (FAQs)

1. What is CIOMS in pharmacovigilance?

CIOMS is an international scientific organization that develops ethical and methodological guidance used in global pharmacovigilance.

2. What is the role of WHO in pharmacovigilance?

WHO coordinates global drug safety monitoring through programs such as the Programme for International Drug Monitoring and the VigiBase database.

3. What is the difference between CIOMS, WHO, and ICH?

CIOMS provides scientific guidance, WHO focuses on global public health monitoring, and ICH develops harmonized regulatory guidelines.

Conclusion

CIOMS and WHO together strengthen the scientific, ethical, and public health foundations of pharmacovigilance. While CIOMS develops conceptual frameworks and ethical guidance, WHO supports global medicine safety monitoring through international collaboration and pharmacovigilance programs.

Along with ICH regulatory guidelines, these organizations form the backbone of the global pharmacovigilance system that protects patients and ensures the safe use of medicines worldwide.